Thursday 25. 4. 2013.

PRE-CONGRESS TRAINING COURSE (12:00-18:00)

Pre-congress training course is free for all Government employees, Healthcare Institutions, students, residents and scientific associates. All attendees should bring their personal computers (laptops) so they can actively participate in the workshop.

**Kalo, Vitezić, Boehler, Helter, Meyer:** Implementation of Evidence Based Health Policy in Lower Income European Economies

12:00  **Plenary session (with international speakers):** Introduction into evidence based health policy, HTA based example, Innovation aspects, Societal perspective, Multicriteria Decision Analysis, Outcomes based risk-sharing, Limitations of HTA transferability

13.30  **Lunch Break**

14:15  **Group Work:** policymaking exercise in groups (computer exercise with Markov models); Case 1: expensive drug therapy (e.g. biological cancer drug), Case 2: targeted therapy (diagnostics + drug combo); group presentations and rehearsal

16:00  **Coffee break**

16:15  **Roundtable discussion (with public policy decision-makers from the region):** Implementation of Evidence Based Health Policy in the region

*Coffee break (18:00-18:30)*

OPENING CEREMONY AND KEY NOTE LECTURES (18:30-20:00)

*Welcome and opening remarks*

**KNL 1.1. Calvo:** Benefit/risk assessment of medicines as a continuum. The need for a new paradigm

*Welcome cocktail and congress dinner (20:00-23:00)*

Friday 26. 4. 2013.

MORNING PODIUM LECTURES (8:30-11:00)

**PL 2.1.** Bulajić: Drug listing policy in Croatia

**PL 2.2.** Boehler: A new spectre is haunting Europe! International price referencing and its impact on lower income European economies

**PL 2.3.** Van de Vooren: Regional tenders in Italy on biosimilars, potentially competitive?

**PL 2.4.** Bochenek: Pharmaceutical pricing and reimbursement in Poland - landscape after a first year of reforms

**PL 2.5.** Garattini: Optional copayments on anti-cancer drugs, is it an option?

*Coffee break (11:00-11:30)*

MORNING PODIUM LECTURES (11:30-13:00)

**HTA Symposium: Cooperation between HTA bodies: EUnetHTA approach**

**PL 3.1.** Meyer: TBC

**PL 3.2.** Goettsch: Towards a European model in relative effectiveness assessment?

**PL 3.3.** Cerbo: Testing European collaboration on production of HTA information

**PL 3.4.** Huić: Health Technology Assessment (HTA) in Croatia: national and international view

*Lunch break (13:00-14:00)*

AFTERNOON PODIUM LECTURES (14:00-15:30)

**PL 4.1.** Behmane: Concept of workability in Health Technology Assessment: Fit for Work Latvia project approach

**PL 4.2.** Morović-Vergles: Fit for Work Croatia

**PL 4.3.** Hren: An importance of sensitivity analyses in health technology assessments is often understated

**PL 4.4.** Kozareva: Comparation of Macedonian and EU policies on pricing and reimbursement
PL 4.5. **Helter**: Moving beyond QALYs - measuring and valuing outcomes of alcohol misuse interventions

*Coffee break (15:30-16:00)*

**POSTER PRESENTATIONS (16:00-16:30)**

**AFTERNOON PODIUM LECTURES (16:30-18:00)**

PL 5.1. **Vas**: Innovative drug research in Central Europe: a dream or reality?
PL 5.2. **Vukičević**: Cost and value of innovation in 21st century
PL 5.3. **Kalo**: Contribution of clinical trials to the economy in Central-Eastern Europe - the case of Hungary
PL 5.4. **Vitezic**: Benefits of clinical trials: focus on economic impact

**ROUND TABLE DISCUSSION (18:00-18:45)**

Clinical Pharmacology, Pharmacoeconomics & HTA

*Congress gala dinner (20:00-23:30)*

*Saturday 27. 4. 2013.*

**MORNING PODIUM LECTURES (8:30-11:00)**

PL 6.1. **Fürst**: Pharmacotherapy groups and clinical pharmacist’s consultations
PL 6.2. **Buble**: Drug pricing and reimbursement policy development in Republic of Croatia
PL 6.3. **Gavrankapetanović**: Prescription habits and drug expenditure in Canton Sarajevo, Bosnia and Herzegovina
PL 6.4. **Hristova**: Pricing of medicines in Republic of Macedonia and importance of pharmacoeconomy in Health insurance fund reimbursement policies
PL 6.5. **Bolanča**: Access to innovation in Croatia

*Coffee break (11:00-11:30)*

**MORNING PODIUM LECTURES (11:30-13:00)**

PL 7.1. **Martinović**: Market overview and challenges for pharma industry in Bosnia and Herzegovina
PL 7.2. **Krehić**: Comparison of the cost per DDD for main therapeutic groups in the Federal Essential List in BIH
PL 7.3. **Loga-Zec**: Patients’ adherence to medication rate and pharmacoeconomic analysis
PL 7.4. **Atanasijević**: Health Technology Assessment in Serbia

*Lunch Break (13:00 - 14:00)*

**AFTERNOON PODIUM LECTURES (14:00-15:30)**

PL 8.1. **Krnarić**: Clinical outcomes of detection and treatment of malnutrition in Croatia
PL 8.2. **Benkovic**: Economic burden of malnutrition in Croatia - a cost of illness study
PL 8.3. **Stevanović**: Decreasing economic burden of resistant hypertension - challenges in market access for medical devices
PL 8.4. **Pankov**: The costs of diabetes in Macedonia
PL 8.5. **Bosak**: Evidence based decision making in medical devices & diagnostics: Are we to benefit from newly proposed European Medical Device Directive?

*Coffee break (15:30-16:00)*

**AFTERNOON PODIUM LECTURES (16:00-17:30)**

**ISPOR Croatia Symposium**

PL 9.1. **Bilušić**: ISPOR tools for health care decision makers
PL 9.2. **Čulić**: Patients’ adherence to medication rate and pharmacoeconomic analysis
PL 9.3. **Leppe**: Estimates of reliability adherence self-reporting scales by the coefficient of internal consistency reliability (Cronbach’s α)
PL 9.4. **Draganić**: Utilisation trends of antihypertensive drugs in Croatia during the period 2008-2011. Comparison between same other countries
PL 9.5. **Čulić**: The most common chronic diseases and adherence to drugs

*Closing ceremony (17:30-18:00)*